Business
NetworkNewsWire Announces Publication Discussing Advances in Cannabinoid-Based Therapies
New York, New York--(Newsfile Corp. - December 14, 2017) - NetworkNewsWire ("NNW"), a multif...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication Discussing Advances in Cannabinoid-Based TherapiesNew York, New York--(Newsfile Corp. - December 14, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.The publication, titled, \"The Therapeutic Potential of Pharmacologically Active Cannabinoids,\" highlights InMed's proprietary technology and the application of certain cannabinoids to treat peripheral pain.To view the full publication, visit: https://www.networknewswire.com/therapeutic-potential-pharmacologically-active-cannabinoids/\"Biosynthesis is the preparation of biological molecules using catalysts derived from natural substances, which are then converted into other compounds. As an example, millions of diabetics use insulin produced via biosynthesis. InMed's proprietary biosynthetic process produces cannabinoids that are identical to naturally occurring compounds and is transformative in ensuring the pharmaceutical standards for therapeutic cannabinoids. This novel breakthrough gives InMed the ability to bio-identically manufacture every cannabinoid compound found in nature and the ability to consistently, reliably and accurately test the compounds' therapeutic efficacy and safety.\"InMed employs a proprietary bioinformatics drug and disease-targeting tool in conjunction with its biosynthesis process. Bioinformatics is a high-efficiency, computer-assisted approach to predicting the therapeutic potential and medicinal properties of individual cannabinoids against particular medical conditions. InMed's approach applies comprehensive algorithms to combine data from various bioinformatics databases with its proprietary cannabinoid database.\"These systems give the company significant competitive advantage. To protect this invaluable asset, InMed has filed a provisional patent for the biosynthesis of cannabinoids (http://nnw.fm/RPTj0), using the process as a base to expand its pipeline of drug candidates. InMed's current pipeline includes INM-750 to treat epidermolysis bullosa, a rare...